Clinical significance of sCD86 levels in patients with acute myelogenous leukemia

Peer review under responsibility of Alexandria University Faculty of Medicine

Available online 12 June 2011

Figures & data

Table 1 Levels of sCD86 in AML patients.

Case number	sCD86 (U/ml)		Control
	Before	After
1	61	11	29.4
2	20	14.1	23.4
3	39	13.6	21.4
4	9.2	4.8	20.2
5	15.8	7.6	23.4
6	19.4	18	19
7	31	18.4	10
8	66.3	23.6	27.6
9	61	24	3
10	29	15	9.4
11	31	12	5.4
12	39	13	5.2
13	32	12.4	3.8
14	52	21	5
15	96.1	5.4	6.6
16	96	14.6	11.6
17	22.8	13	8.4
18	35.4	27	18
19	40	10.2	19.4
20	89.6	79	19
21	48.8	15
22	6.6	6.4
23	87.3	26.4
24	9.4	5
25	26	14.2
26	20	16.6
27	62	3.4
28	7.2	5
29	11.6	6.4
30	18.6	6
Range	6.6 – 96.1	3.4–79	3–29.4
Mean	39.44	15.4	14.46
S.D	27.08	13.7	8.49

Figure 1 Distribution of AML patients according to the positivity for sCD86 before treatment.

Table 2 Relation between outcome and FAB subtype.

			Outcome		Total
			CR	No CR
FAB	M0	No.	1	1	2
		%	9.1%	5.3%	6.7%
	M1	No.	1	3	4
		%	9.1%	15.8%	13.3%
	M2	No.	3	9	12
		%	27.3%	47.4%	40%
	M4 and M5	No.	6	6	12
		%	54.5%	31.6%	40%
Total		No.	11	19	30
		%	100%	100%	100%

Figure 2 Comparison between levels of sCD86 (before and after treatment) and control group.

Table 3 Correlation coefficient between level of sCD86 before and after treatment and white blood cells.

		sCD86 before	sCD86 after
WBCs	r	0.374(^*)	−0.121
	p	0.042	0.525

* Denotes significant correlation.